Objective: To investigate the significance of variation in ADGRV1 (also known as GPR98, MASS1, and VLGR1), MEF2C, and other genes at the 5q14.3 chromosomal locus in myoclonic epilepsy. Methods: We studied the epilepsy phenotypes of 4 individuals with 5q14.3 deletion and found that all had myoclonic seizures. We then screened 6 contiguous genes at 5q14.3, MEF2C, CETN3, MBLAC2, POLR3G, LYSMD3, and ADGRV1, in a 95-patient cohort with epilepsy and myoclonic seizures. Of these genes, point mutations in MEF2C cause a phenotype involving seizures and intellectual disability. A role for ADGRV1 in epilepsy has been proposed previously, based on a recessive mutation in the Frings mouse model of audiogenic seizures, as well as a shared homologous region with another epilepsy gene, LGI1. Results: Six patients from the myoclonic epilepsy cohort had likely pathogenic ultra-rare ADGRV1 variants, and statistical analysis showed that ultra-rare variants were significantly overrepresented when compared to healthy population data from the Genome Aggregation Database. Of the remaining genes, no definite pathogenic variants were identified. Significance: Our data suggest that the ADGRV1 variation contributes to epilepsy with myoclonic seizures, although the inheritance pattern may be complex in many cases. In patients with 5q14.3 deletion and epilepsy, ADGRV1 haploinsufficiency likely contributes to seizure development. The latter is a shift from current thinking, as MEF2C haploinsufficiency has been considered the main cause of epilepsy in 5q14.3 deletion syndrome. In cases of 5q14.3 deletion and epilepsy, seizures likely occur due to haploinsufficiency of one or both of ADGRV1 and MEF2C.
The seizure phenotype in 5q14.3 microdeletion syndrome typically involves infantile onset of febrile seizures, infantile spasms, and myoclonic seizures. [4] [5] [6] [7] Brain structural abnormalities are common and include decreased white matter volume, periventricular heterotopia, and polymicrogyria. 8, 9 A neurocutaneous syndrome involving intracranial and dermatologic vascular malformations has also been described. [10] [11] [12] The underlying genetics of 5q14.3 deletion epilepsy is complex. Current literature points to MEF2C (OMIM 600662) haploinsufficiency playing the most important role, largely based on identification of intragenic mutations of this gene in patients with intellectual disability, stereotypies, and infantile-onset epilepsy, which may include infantile spasms, and myoclonic, atonic, generalized tonicclonic, focal impaired awareness, atypical absence, and hemiclonic seizures. 4, 5, 7, [13] [14] [15] However, MEF2C lies outside the deleted region in at least 5 reported cases of 5q14.3 deletion syndrome, 8, 9, 16, 17 so a role for other genes at the 5q14.3 locus is likely. A prime candidate is ADGRV1 (OMIM 602851; previously known as GPR98, MASS1, VLGR1), affected in 4 of the 5 5q14.3 deletion cases which exclude MEF2C. ADGRV1 encodes adhesion G protein-coupled receptor V1, a large calcium-binding protein widely expressed in the central nervous system. 18, 19 ADGRV1 shares some common features with an established epilepsy gene, LGI1 (OMIM 604619), associated with autosomal dominant epilepsy with auditory features. 20, 21 Both genes encode proteins that share a 7-fold repeated 44-residue motif homology domain, that has been termed an epilepsy-associated region (EAR) domain. 22 In humans, ADGRV1 mutations are associated with Usher syndrome IIC (OMIM 605472), an autosomal recessive condition involving retinitis pigmentosa and progressive hearing loss, without epilepsy. 23 A homozygous truncating mutation in the mouse ortholog, Adgrv1, causes audiogenic reflex seizures in the Frings mouse. 24 In humans, screening for ADGRV1 mutations in 48 families with febrile seizures identified 1 in which a heterozygous truncating mutation was found in 2 affected siblings, both of whom would be classified as febrile seizures plus (FS+), as well as their unaffected father. 25, 26 We identified 3 patients with chromosome 5q14.3 microdeletions; the common deletion region included 5 genes, but excluded MEF2C. An additional patient was identified with a complex chromosome 5 rearrangement, also resulting in a 5q14.3 microdeletion. Detailed phenotyping found that all 4 patients had myoclonic epilepsy. We then hypothesized that variants in genes at this locus might be present in patients with other epilepsy syndromes, and thus screened for variants in 6 genes, including ADGRV1 and MEF2C, in a cohort of 95 patients with epilepsy with myoclonic seizures. Our results suggest that ADGRV1 variation may be an important contributor to the development of genetic epilepsies, particularly those with myoclonic seizures.
| METHODS

| 5q14.3 deletion epilepsy phenotyping and molecular analysis
We studied the epileptology of 4 patients with de novo heterozygous deletions of 5q14.3, including 1 with a complex chromosome 5 inversion. The boundaries of each deleted region were clarified with single nucleotide polymorphism microarray. A 100K GeneChip Affymetrix (50K Hind III; 50K Xbal) was used, and data were analyzed with the GeneChip Chromosome Copy Number Analysis Tool software.
| Cohort of patients with epilepsy with myoclonic seizures
A cohort of 95 patients with myoclonic seizures and epilepsy was assembled from our epilepsy genetics research database. Each patient underwent detailed electroclinical assessment and seizures were classified according to the International League Against Epilepsy (ILAE) Classification. 27, 28 The cohort was composed of 41 patients with genetic generalized epilepsy (GGE), 46 with developmental and/or epileptic encephalopathies, and 8 with unclassified epilepsies.
| Variant screening in the myoclonic epilepsy cohort
We used high-resolution melt (HRM) analysis and/or sequencing to screen for variants in the 5 genes found in the common deleted region of patients 1-3 (CETN3, A multiple ligation-dependent probe amplification (MLPA) assay was also performed to screen for deletions or duplications in the coding regions of MEF2C and ADGRV1. MLPA reagents were obtained from MRCHolland, and a custom-made MLPA was designed using the Human MLPA Probe Design web-based software (http:// genomics01.arcan.stonybrook.edu/mlpa/cgi-bin/mlpa.cgi). [29] [30] [31] An ADGRV1 single-color MLPA assay was designed with the maximum number of synthetic oligonucleotide probes targeting 13 exonic fragments from the 90 coding regions. These regions encompassed the Calx-b domains (exons 23, 70), the EAR domains (exons 44, 49), the transmembrane domains (exons 83, 85, 86, 87), and other exonic fragments (exons 3, 31, 53, 74, 78) located between the Calx-b domains in the extracellular portion of ADGRV1. The MEF2C MLPA was designed to encompass all 10 exons and included 2 regions within the promoter.
DNA samples with heteroduplex variants were subsequently reamplified and sequenced to identify the variation.
| Evaluating pathogenicity of variants
Variants were evaluated for pathogenicity based on their frequency in the Genome Aggregation Database (gnomAD), 32 as well as in silico testing that included Polyphen-2, Mutation Taster, Genomic Evolutionary Rate Profiling, and Grantham scores. Variants were classified as "ultra-rare" if they were absent in gnomAD and "rare" if allele frequency (AF) was < 0.0005. We sequenced parental DNA when available to determine if variants were inherited or de novo. Classification of pathogenicity was dictated by the American College of Medical Genetics and Genomics (ACMG) standards and guidelines. 33 We undertook statistical analysis using gnomAD data to investigate whether the findings of rare and ultra-rare variants might occur by chance and not have biological significance. In the gnomAD database of~246 000 alleles with good coverage of ADGRV1, there are 15 765 rare missense/LOF variants with AF < 0.0005 including 1794 variants present only once. We compared the proportion of rare and ultra-rare variants in our myoclonic epilepsy population to gnomAD data using Fisher's exact test. This statistical approach requires a simplified model in which no allele carries more than 1 variant; however, this is still a reasonable method to estimate whether rare and ultra-rare variants are overrepresented.
The study was approved by the Human Research Ethics Committee of Austin Health, Project No. H2007/02961. Informed, written consent was obtained from all subjects, or their legal guardians.
| RESULTS
| Patients with de novo 5q14.3 deletions
The clinical-molecular features of the 3 patients with 5q14.3 microdeletions and the fourth patient with a complex chromosome 5 inversion-deletion are summarized in Table 1 . Details of the copy number variants are provided in Table S1 ; the molecular data, as well as limited clinical detail, from patients 1-3 have been published previously.
9,34 The 3 straightforward deletions shared a 1.34 Mb common deleted region affecting 5 genes: CETN3 (OMIM 602907); MBLAC2; POLR3G; LYSMD3; and ADGRV1 ( Figure 1 ). The fourth patient had a small 5q14.3 deletion (2.3 Mb) and a large inversion encompassing 5q14-23.1 (13.9 Mb). Notably, MEF2C was not included in the overlapping region of all 4 cases; in patient 3, only the MEF2C anti-sense RNA was affected. Briefly, all 4 patients had neonatal or infantile-onset epilepsy with myoclonic and generalized tonic-clonic seizures, with the latter provoked by fever in 2. Exaggerated startle was noted in patients 1 and 3, with patient 3 also having prominent reflex myoclonic seizures, triggered by auditory or tactile stimulation. Atypical absence seizures occurred in patients 2 and 4. Electroencephalography (EEG) showed generalized spike-wave or polyspike-wave discharges. All patients had severe to profound developmental impairment, and were classified as having myoclonic developmental and epileptic encephalopathy. With respect to vision and hearing impairment, patient 3 had conductive hearing loss and visual impairment, and patient 2 had strabismus and horizontal nystagmus. (Table 2 ). These variants were also absent in our control group, except for NM_032119.3: c.7342G>A, which was found in 1 control. All 5 variants were in the extracellular protein domain, and all but 1 (NM_032119.3: c.5857A>C) were in Calx-b motifs. One variant (NM_032119.3: c.530C>G) was recurrent, present in 2 unrelated patients; proven de novo in 1, and bi-parental testing was not possible in the other. The 6 patients carrying these variants had a variety of epilepsy phenotypes (Table 2) including juvenile myoclonic epilepsy (JME; 2), Lennox-Gastaut syndrome (LGS; 2), early onset absence epilepsy with later myoclonic seizures and mild intellectual disability (1), and GGE (1). All but 1 of the patients had a positive family history of epilepsy in at least one first-or second-degree relative. Two variants were inherited, 1 from a mother with unclassified epilepsy and the other from a father without a history of seizures. Based on ACMG criteria, 4 of the variants are likely pathogenic and 1 is of uncertain significance.
In addition to the ADGRV1 variants absent in gnomAD, we identified 8 rare (AF < 0.0005 in gnomAD) variants in 7 patients, which were also absent in our control group (NM_ 032119. Table S3 ). In silico testing predicted that 7 of the variants were at least possibly damaging based on Polyphen-2 and Mutation Taster scores, with the remaining variant predicted to be benign by Polyphen-2 and Mutation Taster, but having (Table S1 ).
a very high Grantham score of 194 (Table S3 ). These patients also had a variety of epilepsy phenotypes, including JME (2), GGE (2), LGS (2), and atypical childhood epilepsy with centrotemporal spikes with negative myoclonus (ACECTS; 1). The patient with ACECTS carried 2 ADGRV1 variants (NM_032119.3: c.8266G>A and NM_ 032119.3: c.13228G>A). These variants were classified as of uncertain significance by ACMG criteria. Our statistical analysis showed that based on gnomAD data, we would expect to identify~12 rare and~1.5 ultrarare ADGRV1 missense/loss of function (LOF) variants in our 95-patient cohort; thus our findings of 14 rare variants, including 6 ultra-rare, suggests an overrepresentation. Using Fisher's exact test to compare proportions, the proportions of rare variants are not statistically different (P = 0.55); however, there are more ultra-rare variants in the epilepsy group than would be expected (P = 2.9 9 10
À3
). This estimate suggests that the probability of this proportion of ultra-rare variants occurring by chance is < 0.003%.
For POLR3G, a single ultra-rare variant was found (NM006467.2: c.532G>A), not present in gnomAD, but predicted benign by in silico analysis. For LYSMD3, a single rare variant was identified (NM_198273.2: c.769T>A), present 79 times in gnomAD (AF 0.0003), predicted possibly damaging by in silico analysis. Neither of these variants was considered to be pathogenic. For CETN3, MBLAC2, and MEF2C, only known minor allelic variants were identified. MLPA did not reveal any deletions or duplications in MEF2C or ADGRV1.
| DISCUSSION
The underlying genetics of the epilepsies associated with the severe 5q14.3 deletion syndrome is complicated, as evidenced by the lack of a common deletion region. This suggests that pathogenesis is due to haploinsufficiency of multiple genes or, alternatively, that disruption of nearby regulatory elements has effects on a specific causal gene.
At present, the epilepsy has been attributed primarily to haploinsufficiency of MEF2C, a member of the myocyte enhancer factor-2 family of transcription factors. 35 Patients with intragenic MEF2C mutations have multiple abnormalities including intellectual disability, stereotypies, and infantile-onset epilepsy, which may include infantile spasms, and myoclonic, atonic, generalized tonic-clonic, focal impaired awareness, atypical absence, and hemiclonic seizures. 4, 5, 7, [13] [14] [15] The reflex seizures in our 5q14.3 deletion cohort have not previously been reported, and are reminiscent of observations in the recessive animal model, the Frings mouse, supporting a role for ADGRV1. Two patients had exaggerated startle or reflex myoclonic seizures, similar to the reflex seizures that characterize the Frings mouse with Adgrv1 mutation. Reflex myoclonic seizures have also not been reported with intragenic MEF2C mutations, raising the possibility that ADGRV1 disruption may be contributing to the epilepsy phenotype in patients with 5q14.3 deletion.
We identified rare or ultra-rare ADGRV1 variants in 13 of 95 (14%) of a cohort of epilepsy patients with myoclonic seizures. Six of the 95 patients (6%) carried ultra-rare (not present in gnomAD) variants that were considered to be likely pathogenic, with an additional 7 patients (7%) carrying rare variants of uncertain significance. These findings suggest that ADGRV1 may play a role in up to 6% of myoclonic epilepsies. The pattern of inheritance is likely complex in the majority; however, although some cases may contribute via an oligogenic mechanism, others may cause epilepsy in an autosomal dominant manner. Most notably, the recurrent mutation (NM_032119.3: c.530C>G) that occurred de novo in 1 patient, with parental testing not available in the other, was predicted to be damaging by in silico testing, and was not present in gnomAD. We did not identify any likely pathogenic variants in MEF2C or the remaining 4 genes in the region.
ADGRV1 is a very large gene, encoding 90 exons and spanning 600 kb of genomic sequence 36 ; given this, we undertook statistical analysis using gnomAD data to investigate whether the findings of rare and ultra-rare variants might occur by chance and not have biological significance. This analysis allowed us to confidently state that ultra-rare ADGRV1 variants are overrepresented in our myoclonic epilepsy cohort (P = 2.9 9 10 À3 ), supporting our hypothesis that they are likely pathogenic. Because homozygous ADGRV1 mutations cause Usher syndrome IIC, the lack of reported seizures in these families appears surprising at first. 37 However, of reported homozygous mutations associated with Usher IIC, most result in frameshift/truncation, 23,37-39 while we have reported only heterozygous missense mutations in our epilepsy cohort. Furthermore, Ebermann et al. demonstrated that variants in PDZD7 act as modifiers in Usher IIC, and that digenic inheritance with PDZD7 and ADGRV1 can occur, findings which suggested that Usher IIC can be considered an oligogenic syndrome rather than having straightforward Mendelian autosomal recessive inheritance. 38 From a pathophysiologic perspective, Usher IIC likely occurs when the complete absence or lack of function of the ADGRV1 protein leads to dysfunction of the Usher protein network, and consequent sensorineural degeneration in the retina and inner ear. 40 In our epilepsy cohort, missense mutations presumably led to ADGRV1 protein dysfunction, which results in seizures via a different pathway that has yet to be clarified. Although the mechanism by which ADGRV1 haploinsufficiency leads to epilepsy remains unclear, recent animal model work may provide early insight into the nature of pathogenicity. Lib e-Philippot et al. recently found that Adgrv1 is required for c-aminobutyric acid (GABA)ergic interneuron development in the auditory cortex. 41 Widespread cortical GABAergic cell dysfunction is a potential epileptogenic mechanism in humans that could have treatment implications; however, further work is necessary to determine if this is, in fact, the case. In summary, based on currently available data, disruption of ADGRV1 may be an important etiologic factor in epilepsy with myoclonic seizures, as well as other genetic epilepsy phenotypes. Moreover, in 5q14.3 deletion syndrome, ADGRV1 haploinsufficiency likely contributes to the phenotype, which may involve 1 or more of febrile seizures, myoclonic seizures, infantile spasms, generalized tonic-clonic seizures, and atypical absences. Exaggerated startle is also seen in patients with 5q14.3 deletion, and may occur because of disruption of ADGRV1. Point mutations in ADGRV1 may also cause a variety of epilepsy syndromes including JME, other GGE, and LGS, although the inheritance pattern is likely complex in many individuals.
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